Featured Research

from universities, journals, and other organizations

Rheb's Role In Cancer

Date:
August 20, 2008
Source:
Cold Spring Harbor Laboratory
Summary:
Two independent papers identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.

Two independent papers in the August 15th issue of Genes & Development identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.

The first paper, from Dr. Pier Paolo Pandolfi (BIDMC and Harvard Medical School) and colleagues, demonstrates that the Ras-like small GTPase, Rheb, is directly involved in prostate tumorigenesis.

Through the overexpression of Rheb specifically in prostate tissue of live mice, the researchers were able to show that increased Rheb signaling activity is sufficient to induce low-grade prostate neoplasias. Furthermore, in combination with decreased PTEN activity, Rheb overexpression can stimulate aggressive prostate tumor formation.

"The identification of Rheb as a gene involved in the pathogenesis of cancer opens new avenues for the development of anti-cancer therapies, as Rheb is an inherently 'druggable' target. Indeed, we are already testing such drugs alone, and in combination with other chemotherapeutics in faithful animal models," explains Dr. Pandolfi.

In the accompanying paper, Dr. Hans-Guido Wendel (Memorial Sloan Kettering Cancer Center) and colleagues present evidence that Rheb can also function as an oncogene in lymphomagenesis.

Using an experimental animal model of human lymphoma, the researchers demonstrated that Rheb overexpression contributes to lymphoma formation. They also pinpointed Rheb overexpression as a naturally occurring genetic mutation in human patient-derived lymphoma tumor samples. In addition, Dr. Wendel and colleagues found that the targeted inhibition of Rheb can effectively counteract tumor progression in lymphomas with this unique genetic signature.

Dr. Wendel emphasizes that "The key clinical implication is that Rheb levels in tumor tissue could indicate patients that will benefit from relatively non-toxic therapies with targeted drugs like rapamyicn or inhibitors of the farnesyltransferase enzyme."


Story Source:

The above story is based on materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Journal References:

  1. Nardella et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes & Development, 2008; 22 (16): 2172 DOI: 10.1101/gad.1699608
  2. Mavrakis et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes & Development, 2008; 22 (16): 2178 DOI: 10.1101/gad.1690808

Cite This Page:

Cold Spring Harbor Laboratory. "Rheb's Role In Cancer." ScienceDaily. ScienceDaily, 20 August 2008. <www.sciencedaily.com/releases/2008/08/080814171122.htm>.
Cold Spring Harbor Laboratory. (2008, August 20). Rheb's Role In Cancer. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/08/080814171122.htm
Cold Spring Harbor Laboratory. "Rheb's Role In Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/08/080814171122.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins